Purple biotech reports additional positive interim results from its randomized phase 2 pancreatic cancer study with cm24 regarding a potential predictive biomarker for overall survival benefit

Rehovot, israel, june 27, 2024 (globe newswire) --  purple biotech ltd. (“purple biotech” or “the company”) (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today reported additional positive interim data from its randomized, controlled, open label, multicenter phase 2 study (nct 04731467) of cm24, in combination with bristol myers squibb's immune checkpoint inhibitor nivolumab and standard of care (soc) chemotherapy, in second-line metastatic pancreatic ductal adenocarcinoma (pdac). these results suggest that serum mpo may be a predictive biomarker for survival in the cm24+nivolumab + nal-iri/5fu/lv arm. the company also announced that it will host a virtual kol event on thursday, july 11, 2024 at 10:30 am et to discuss the results in detail. to register for the event, click here.
PPBT Ratings Summary
PPBT Quant Ranking